NeuroSense Therapeutics NRSN
NASDAQ NRSN
$2.58 +0.19 (+7.88%)
As of: Oct 21, 2026 · 2:23 PM EDT

NeuroSense Therapeutics (NRSN) EBIT (2021 - 2024)

Updated

NeuroSense Therapeutics (NRSN) reported EBIT of -$11.09 million for FY2025, compared with -$9.9 million in FY2024.

Analysis

NeuroSense Therapeutics (NRSN) EBIT (2021 - 2024) Analysis & Trends

Dating back to FY2019, NeuroSense Therapeutics' EBIT record includes 7 years.

  • Five-year annual EBIT spans a low of -$12.05 million in FY2023 and a high of -$2.99 million in FY2021.
  • According to Business Quant data, EBIT came in at -$9.9 million in FY2024, -$12.05 million in FY2023, -$10.55 million in FY2022 and -$2.99 million in FY2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT (Qtr)
1 Eli Lilly 1,135.59 Bn 1,104.17 Bn 19.71 Bn 11.75 Bn
2 Johnson & Johnson 616.92 Bn 535.45 Bn 17.26 Bn 7.14 Bn
3 AbbVie 501.52 Bn 474.63 Bn 12.70 Bn 6.43 Bn
4 Merck 367.36 Bn 321.74 Bn 12.21 Bn -584.00 Mn
5 Novartis Ag 297.93 Bn 261.92 Bn 11.24 Bn 4.75 Bn
6 Astrazeneca 261.45 Bn 235.14 Bn 12.86 Bn 3.16 Bn
7 Amgen 236.40 Bn 191.80 Bn 7.24 Bn 3.51 Bn
8 Gilead Sciences 190.72 Bn 164.92 Bn 6.22 Bn -10.39 Bn
9 Pfizer 169.43 Bn 116.08 Bn 10.94 Bn 4.27 Bn
10 NeuroSense Therapeutics 3.28 Mn -1.16 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 -1.77 Mn
Sep 30, 2024 -2.11 Mn
Jun 30, 2024 -3.03 Mn
Mar 31, 2024 -2.99 Mn
Dec 31, 2023 -3.06 Mn
Sep 30, 2023 -2.63 Mn
Jun 30, 2023 -3.37 Mn
Mar 31, 2023 -2.99 Mn
Dec 31, 2022 -381,000.00
Sep 30, 2022 -3.32 Mn
Jun 30, 2022 -3.59 Mn
Mar 31, 2022 -3.26 Mn
Dec 31, 2021 957,000.00
API Access

NeuroSense Therapeutics EBIT API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit&ticker=NRSN&period=max&api_key=YOUR_API_KEY